The Manufacturers Life Insurance Company Acquires Shares of 63,219 Qiagen N.V. $QGEN

The Manufacturers Life Insurance Company bought a new position in Qiagen N.V. (NYSE:QGEN) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm bought 63,219 shares of the company’s stock, valued at approximately $2,518,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Banque Cantonale Vaudoise grew its position in shares of Qiagen by 1.8% in the fourth quarter. Banque Cantonale Vaudoise now owns 16,363 shares of the company’s stock valued at $747,000 after purchasing an additional 290 shares in the last quarter. Commerce Bank lifted its position in Qiagen by 4.9% during the fourth quarter. Commerce Bank now owns 6,725 shares of the company’s stock worth $302,000 after buying an additional 314 shares in the last quarter. Truist Financial Corp lifted its position in Qiagen by 4.1% during the fourth quarter. Truist Financial Corp now owns 8,421 shares of the company’s stock worth $379,000 after buying an additional 331 shares in the last quarter. Private Advisor Group LLC boosted its stake in Qiagen by 7.1% during the third quarter. Private Advisor Group LLC now owns 5,730 shares of the company’s stock worth $256,000 after buying an additional 378 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in Qiagen by 4.1% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 10,322 shares of the company’s stock worth $485,000 after buying an additional 402 shares during the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Citigroup reaffirmed a “hold” rating on shares of Qiagen in a research note on Monday, May 18th. Jefferies Financial Group reissued a “buy” rating and issued a $48.00 price objective on shares of Qiagen in a report on Thursday. Stifel Nicolaus set a $40.00 price objective on shares of Qiagen in a research report on Friday. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $43.00 target price on shares of Qiagen in a research note on Thursday, April 30th. Finally, Zacks Research upgraded shares of Qiagen from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $43.34.

Qiagen Price Performance

QGEN stock opened at $42.28 on Friday. Qiagen N.V. has a 52-week low of $32.53 and a 52-week high of $57.81. The company has a quick ratio of 2.57, a current ratio of 3.21 and a debt-to-equity ratio of 0.49. The stock has a market cap of $8.71 billion, a price-to-earnings ratio of 21.66, a price-to-earnings-growth ratio of 4.21 and a beta of 0.63. The business has a fifty day moving average of $39.43 and a two-hundred day moving average of $41.69.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.60 by $0.02. The business had revenue of $535.04 million for the quarter, compared to analyst estimates of $527.50 million. Qiagen had a return on equity of 14.24% and a net margin of 19.49%.The company’s quarterly revenue was up .2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.60 EPS. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, research analysts anticipate that Qiagen N.V. will post 2.43 earnings per share for the current year.

Qiagen Increases Dividend

The business also recently announced an annual dividend, which was paid on Tuesday, July 14th. Shareholders of record on Tuesday, July 7th were given a $0.35 dividend. The ex-dividend date of this dividend was Tuesday, July 7th. This is an increase from Qiagen’s previous annual dividend of $0.26. This represents a yield of 90.0%. Qiagen’s dividend payout ratio is currently 17.95%.

Qiagen Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.